Minimal residual disease in neuroblastoma: to GAGE or not to GAGE

Oncol Res. 2004;14(6):291-5. doi: 10.3727/096504003773994824.

Abstract

We assessed the utility of GAGE gene expression as a marker of minimal residual disease (MRD) in neuroblastoma. The GAGE gene family shows a high degree of homology (>90%), clustering into two subgroups. GAGE-1, -2, and -8 form one subset, almost identical among themselves, while GAGE-3 to -7 constitute the other subset. The entire GAGE family (GAGE-1-8) was studied by RT-PCR followed by Southern blotting to increase both the sensitivity and specificity of the technique. Surprisingly, expression of GAGE was detected in 59% of peripheral blood samples from normal controls (20/35) as well as in a similar proportion from neuroblastoma patients with localized disease (stages 1 and 2). The study of GAGE-1, -2, and -8 with specific primers lowered this percentage to 28% (10/35), of which only two (6%) showed a high level of expression (directly visualized after RT-PCR). We conclude that GAGE genes can show a variable, usually low level of illegitimate expression in normal blood cells, and therefore their use as MRD markers should be taken with caution.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm
  • Base Sequence
  • Biomarkers, Tumor / genetics
  • Bone Marrow / metabolism
  • Gene Expression Regulation, Neoplastic / genetics*
  • Humans
  • Molecular Sequence Data
  • Multigene Family / genetics
  • Neoplasm Proteins / genetics*
  • Neoplasm, Residual / blood
  • Neoplasm, Residual / genetics*
  • Neuroblastoma / blood
  • Neuroblastoma / genetics*
  • Sequence Alignment

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • GAGE1 protein, human
  • Neoplasm Proteins